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Rationale: Renewed interest has been seen in the use of lysergic acid diethylamide
(LSD) in psychiatric research and practice. The repeated use of LSD leads to tolerance
that is believed to result from serotonin (5-HT) 5-HT2A receptor downregulation. In
rats, daily LSD administration for 4 days decreased frontal cortex 5-HT2A receptor
binding. Additionally, a single dose of LSD acutely increased expression of the early
growth response genes EGR1 and EGR2 in rat and mouse brains through 5-HT2A
receptor stimulation. No human data on the effects of LSD on gene expression has
been reported. Therefore, we investigated the effects of single-dose LSD administration
on the expression of the 5-HT2A receptor gene (HTR2A) and EGR1-3 genes.
Methods: mRNA expression levels were analyzed in whole blood as a peripheral
biomarker in 15 healthy subjects before and 1.5 and 24 h after the administration of
LSD (100 µg) and placebo in a randomized, double-blind, placebo-controlled, cross-
over study.
Results: LSD did not alter the expression of the HTR2A or EGR1-3 genes 1.5 and 24 h
after administration compared with placebo.
Conclusion: No changes were observed in the gene expression of LSD’s primary target
receptor gene or genes that are implicated in its downstream effects. Remaining unclear
is whether chronic LSD administration alters gene expression in humans.
Keywords: LSD, serotonin receptor, gene expression, healthy subjects
INTRODUCTION
Lysergic acid diethylamide (LSD) is a well-known psychoactive substance that transiently alters
mind and perception. During the last few years, renewed interest has been seen in the use
of LSD in psychiatric research and practice (Liechti, 2017). Modern experimental studies in
humans have reported LSD’s subjective, autonomic, and endocrine effects (Schmid et al., 2015;
Carhart-Harris et al., 2016a; Dolder et al., 2016; Strajhar et al., 2016; Liechti et al., 2017),
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functional brain activation patterns (Carhart-Harris et al., 2016b;
Lebedev et al., 2016; Tagliazucchi et al., 2016; Preller et al., 2017),
and pharmacokinetics (Dolder et al., 2015b, 2017). However,
many aspects of LSD’s pharmacological effects remain unclear,
including the phenomenon of the rapid development of tolerance
(i.e., tachyphylaxis) to its psychological and physiological effects
with repeated administration (Passie et al., 2008). Early studies
that employed repeated daily administration of 100 µg LSD in
humans described partial tolerance with the second dose and
complete tolerance with the third and subsequent doses (Cholden
et al., 1955; Abramson et al., 1956; Belleville et al., 1956). The
effects of LSD reappeared only after a substance-free interval of
4 days. Tolerance to LSD is believed to result from serotonin
5-HT2A receptor downregulation (Nichols, 2016). LSD potently
binds to the 5-HT2A receptor (Wacker et al., 2017) where it
acts as a partial agonist (Rickli et al., 2016). Pretreatment with
the 5-HT2A receptor antagonist ketanserin completely prevented
all perceptual and mind-altering effects of LSD in humans
(Kraehenmann et al., 2017; Preller et al., 2017), indicating that the
hallucinogenic effects of LSD are primarily mediated through 5-
HT2A receptors. Similar to humans, tolerance to the behavioral
effects of LSD is also observed in rats (Buchborn et al., 2015).
Consistent with a role for 5-HT2A receptors in the development
of tolerance, daily LSD administration for 3 days decreased 5-
HT2A receptor binding in the rat frontal cortex (Buckholtz et al.,
1985, 1990; Gresch et al., 2005). However, another study reported
only a non-significant trend toward a reduction of frontocortical
5-HT2A receptor binding in rats during the development of
tolerance to LSD (Buchborn et al., 2015). Additionally, no effects
of acute LSD on 5-HT2A receptor mRNA expression were found
in the rat prefrontal cortex, hippocampus, or midbrain (Nichols
and Sanders-Bush, 2002), although the effects of repeated
LSD administration were not studied. Instead, adaptations in
glutamate receptors were observed (Buchborn et al., 2015).
Indeed, a key mechanism of action of LSD is the activation
of frontal cortex glutamate transmission secondary to 5-HT2A
receptor stimulation (Gonzalez-Maeso et al., 2008; Moreno et al.,
2011; Buchborn et al., 2015). Thus, adaptive changes that underlie
tolerance to LSD may be reflected by alterations in the expression
of genes that are involved in glutamatergic signaling or genes that
regulate 5-HT2A receptor function or its downstream signaling
pathways. Acute LSD increased the expression of immediate early
genes in the rat prefrontal cortex, including EGR2 (i.e., a gene
that is involved in cognition and neural plasticity) and several
others genes (Nichols and Sanders-Bush, 2002; Nichols et al.,
2003; Nichols and Sanders-Bush, 2004). Further animal studies
showed that LSD also increased the expression of EGR2 and EGR1
in the mouse cortex via 5-HT2A receptor stimulation (Gonzalez-
Maeso et al., 2003, 2007). Finally, LSD was shown to produce a
characteristic transcriptome signaling pattern in normal but not
HTR2A−/− mice (Gonzalez-Maeso et al., 2007).
Despite the renewed interest in the clinical use of LSD, no
human studies on the effects of LSD on gene expression have been
performed. Therefore, we investigated the effects of a single dose
of LSD on the expression of the 5-HT2A receptor gene (HTR2A)
and EGR1-3 genes. The EGR1 and EGR2 genes were studied based
on preclinical data (Gonzalez-Maeso et al., 2003, 2007), and the
EGR3 gene was studied because it has been shown to regulate
HTR2A expression (Maple et al., 2015).
Acute changes in gene expression cannot be determined in
heathy human brain tissue, as biopsy or postmortem tissue
is not available. However, mRNA level changes in blood for
candidate genes including EGR and HTR2A can cautiously be
used as peripheral markers of transcription alterations in the CNS
in response to interventions or to characterize patient groups
(Sullivan et al., 2006; Mohr and Liew, 2007; Desjardins et al.,
2008; Belzeaux et al., 2010; Rollins et al., 2010; Rivera-Baltanas
et al., 2014; Cattane et al., 2015). The EGR and HTR2A genes are
expressed in peripheral blood cells (Stefulj et al., 2000; Fukuda
et al., 2006; Inoue et al., 2011; Cattane et al., 2015). The peripheral
mRNA expression of several genes including the HTR2A gene
were shown to have relatively similar expression profiles as in
brain tissues (Glatt et al., 2005; Fukuda et al., 2006; Sullivan et al.,
2006; Desjardins et al., 2008; Rollins et al., 2010; Yubero-Lahoz
et al., 2015; GTExPortal, 2017). In healthy humans, HTR2A gene
expression levels in whole blood correlated with 5-HT metabolite
levels in the cerebrospinal fluid (Luykx et al., 2016). Peripheral
EGR1 expression was increased in patients with schizophrenia
compared with healthy controls (Cattane et al., 2015).
Therefore, we expected altered HTR2A expression in response
to LSD. Additionally, we hypothesized that LSD acutely increases
EGR1 and EGR2 gene expression in humans similarly to rodents.
MATERIALS AND METHODS
Study Design
The study used a double-blind, placebo-controlled, cross-over
design with two experimental test sessions in balanced order.
The washout periods between sessions were at least 7 days.
The study was conducted in accordance with the Declaration
of Helsinki and International Conference on Harmonization
Guidelines in Good Clinical Practice (ICH-GCP) and approved
by the Ethics Committee of Northwestern Switzerland. The
administration of LSD in healthy subjects was authorized by the
Swiss Federal Office for Public Health, Bern, Switzerland. All of
the subjects provided written informed consent and were paid for
their participation. The study was registered at ClinicalTrials.gov
(NCT02308969).
Participants
Twenty-four healthy subjects (12 men, 12 women; mean
age ± SD: 33 ± 11 years; range: 25–60 years) participated in
the study. Blood samples for gene expression measurements
were taken from only 15 participants (7 men, 8 women;
mean age ± SD: 28.5 ± 5.8 years; range: 25–48 years; mean
weight ± SD: 68 ± 8 kg; range: 55–85 kg; mean BMI ± SD:
22.0 ± 2.0 kg/m2; range: 19–24 kg/m2). The inclusion and
exclusion criteria, subjective, autonomic, and adverse effects
of LSD, and pharmacokinetic data from this study have been
reported in detail elsewhere (Dolder et al., 2016, 2017; Liechti
et al., 2017). Briefly, the participants had to be 25- to 65-years
old and physically and mentally healthy. Additional exclusion
criteria were pregnancy, tobacco smoking (>10 cigarettes/day),
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life-time prevalence of illicit drug use >10 times (except
tetrahydrocannabinol), and illicit drug use within the past
2 months or during the study (determined by urine drug tests).
Of the 15 subjects, only two had used a hallucinogen (LSD and
psilocybin) once in their lives.
Study Procedures
The experimental sessions were conducted in a standard
hospital patient room. The participants were resting in hospital
beds except when going to the restroom. Only one research
participant and one or two investigators were present during the
experimental sessions. The participants could interact with the
investigator, rest quietly, and/or listen to music via headphones,
but no other entertainment was provided. LSD or placebo was
administered at 9:00 AM. A standardized lunch and dinner were
served at 1:30 and 5.30 PM, respectively. The subjects were never
alone during the first 12 h after drug administration, and the
investigator was in a room next to the subject for up to 24 h while
the subject was asleep (mostly from 1:00 to 8:00 AM).
Study Drug
LSD (D-LSD, Lipomed AG, Arlesheim, Switzerland) was
administered in a single oral dose of 100 µg as a capsule. The
dose was within the range of doses that are taken for recreational
purposes (Passie et al., 2008; Nichols, 2016). Corresponding
placebo capsules were used.
Measures
Gene Expression
Blood samples were collected before and 1.5 and 24 h after
drug administration using the PAXgeneTM Blood RNA system
(Becton Dickinson, Heidelberg, Germany). The 1.5 h time
point was selected to coincide with the peak of the plasma
concentration of LSD (Dolder et al., 2015b). The 24 h time
point was selected because partial tolerance by that time has
been documented (Cholden et al., 1955; Abramson et al., 1956;
Belleville et al., 1956). Samples were incubated for 2 h at
room temperature, followed by freezing at −80◦C until further
processing. Total RNA was prepared using the PAXgeneTM Blood
RNA Kit 50 (PreAnalytiX, Qiagen, Hilden, Germany). Total RNA
samples were spectrophotometrically scanned (260 and 280 nm;
NanoVue, GE Healthcare Life Sciences, Glattbrugg, Switzerland).
A260 was used for RNA quantification. The A260/A280 ratio was
>1.9, excluding relevant protein contamination. RNA quality was
also measured using Experion RNA chips (BioRad, Hercules, CA,
United States) providing the RNA quality indicator (RQI > 7).
Quantitative real-time polymerase chain reaction (PCR) was
performed for the HTR2A, EGR1, EGR2, and EGR3 genes and
six additional reference genes (ACTB, GAPDH, ALAS1, RPL13A,
PPIA, and RRN18S) as described previously (Grunblatt et al.,
2009). The investigated genes are listed in detail in Table 1.
Total RNA (500 ng) from each sample was reverse-transcribed
using the iScript cDNA synthesis kit (BioRad, Hercules, CA,
United States). Each amplification was performed in a total
volume of 10 µl that contained 5 µl of the QuantiFast SYBR
Green PCR kit (Qiagen, Hilden, Germany) and the specific
PrimerAssay (Qiagen, Hilden, Germany). The PCR conditions
were run on a CFX384 device (BioRad, Hercules, CA, United
States) according to manufacturer’s manual, with the exception of
HTR2A primers, in which annealing occurred at 56◦C according
to a gradient analysis (Qiagen, Hilden, Germany). A melting-
point analysis was conducted for each assay to confirm the
specificity of the PCR products. All of the PCR reactions were run
in triplicate. LinRegPCR 2016.0 software (Hart Failure Research
Center, Amsterdam, The Netherlands; Ramakers et al., 2003)
was used to determine the PCR efficiency. The analysis of gene
expression and normalization with the most stable reference
genes was conducted using qBasePlus 3.0 software (Biogazelle,
Gent, The Netherlands; Vandesompele et al., 2002). Since the
consensus is that there are no real reference (housekeeping)
genes, there is a need to use more than one reference genes as well
as test them before normalization is conducted (Vandesompele
et al., 2002). The reference genes GAPDH and PPIA were the
least stable and thus excluded, and the normalization analysis
was conducted using the four remaining reference genes (ACTB,
ALAS1, RPL13A, and RRN18S).
Plasma Concentrations of LSD
Blood was collected in lithium heparin tubes before and 1, 2,
3, 4, 6, 8, 10, 12, 16, and 24 h after LSD administration. The
blood samples were immediately centrifuged, and the plasma
was rapidly stored at −20◦C and later at −80◦C until analysis.
LSD concentrations in plasma were determined using liquid-
chromatography-tandem mass-spectrometry as reported in detail
elsewhere (Dolder et al., 2015a; Steuer et al., 2016). The lower
limit of quantification was 0.05 ng/ml (Dolder et al., 2015a). The
pharmacokinetics of LSD from the present study are presented in
detail elsewhere (Dolder et al., 2017).
Statistics
The statistical analyses were performed using Statistica 12
software (StatSoft, Tulsa, OK, United States). Baseline gene
expression values before drug administration were set to 1,
and changes after 1.5 and 24 h are expressed as fold changes
from baseline. Differences between LSD and placebo at the
corresponding time points were then analyzed using paired
t-tests. All comparisons were also made with data standardized
to the mean age, body weight, and peak plasma concentrations
of LSD. The criterion for significance was p < 0.05 without
correction for multiple comparisons. Additionally, to test for
changes in gene expression over time after administration of LSD
or placebo, repeated measures analyses of variance (ANOVAs)
were conducted with time (0, 1.5, and 24 h) as within-subject
factor followed by Tukey post hoc test. To assess potential
moderating effects by sex, sex was added as additional between-
subjects factor to the ANOVAs.
RESULTS
Three samples after 24 h had insufficient amounts of RNA to
be included in the analysis (Table 2). The expression patterns
of the HTR2A, EGR1, EGR2, and EGR3 genes were unchanged
1.5 and 24 h after the administration of LSD compared with
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TABLE 1 | List of investigated genes.
Gene name Abbreviation Qiagen (cat. no.) Gene bank accession no.
Reference genes
β-Actin ACTB∗ QT00095431 NM_001101
Glyceraldehydes-3-phosphate dehydrogenase GAPDH QT00079247 NM_002046
Aminolevulinate delta synthase 1 ALAS1∗ QT00073122 NM_000688
Ribosomal protein L13a RPL13A∗ QT00089915 NM_012423
Peptidylprolyl isomerase A PPIA QT00052311 NM_021130
18s ribosomal RRN18S∗ QT00199367 V01270
Genes of interest
Serotonin 2a receptor HTR2A QT00054306 NM_000621
Early growth response 1 EGR1 QT00218505 NM_001964
Early growth response 2 EGR2 QT00000924 NM_000399
Early growth response 3 EGR3 QT00246498 NM_001199880
NM_001199881 NM_004430
∗Most stable reference genes used for normalization.






HTR2A 1.5 h 15 0.51 (0.13) 0.39
24 h 12 0.07 (0.02) 0.90
EGR1 1.5 h 15 −0.1 (−0.03) 0.83
24 h 12 0.47 (0.14) 0.10
EGR2 1.5 h 15 0.04 (0.01) 0.86
24 h 12 0.27 (0.08) 0.22
EGR3 1.5 h 15 0.20 (0.05) 0.24
24 h 11 0.40 (0.12) 0.16
HTR2A, serotonin 2a receptor gene; EGR, early growth response gene; n, number
of samples. aGene expression values are differences (mean and [SEM]) between
LSD and placebo at the respective time point for fold-changes from baseline;
bt-tests.
placebo (Figure 1 and Table 2). Expression did also not change
over time after LSD and placebo (HTR2A: F2,24 = 0.02, P = 1.0
and F2,26 = 1.24, P = 0.3; EGR1: F2,24 = 1.14, P = 0.3 and
F2,26 = 1.9, P= 0.2; EGR2: F2,24 = 1.20, P= 0.3 and F2,26 = 2.67,
P = 0.09; EGR3: F2,24 = 1.17, P = 0.2 and F2,24 = 0.08, P = 0.9,
respectively). Sex did not moderate the effects of LSD or placebo
on gene expression. Additionally, the findings were similar if the
data was standardized to the mean age, body weight or plasma
concentration of LSD.
DISCUSSION
The key finding of the present study was that acute LSD
administration did not alter the expression of the HTR2A
and EGR1-3 genes in humans using peripheral blood cells as
peripheral biomarker possibly reflecting central gene expression.
The lack of an acute effect of LSD on HTR2A gene expression in
humans is consistent with a study in rats that reported no changes
in HTR2A gene expression in different brain areas (Nichols
and Sanders-Bush, 2002). However, 5-HT2A receptor availability
may also be altered independently of HTR2A gene expression
(e.g., by receptor internalization or moderation of its activity).
Several studies in rats (Buckholtz et al., 1985, 1990; Gresch et al.,
2005; Buchborn et al., 2015) reported a decrease in 5-HT2A
receptor binding in the prefrontal cortex or consistent trend
effects (Buchborn et al., 2015) after repeated LSD administration.
Unknown, however, is whether lower binding also occurs after
single-dose administration. The present findings of no changes
in EGR1 and EGR2 gene expression in human blood samples
after acute LSD administration contrast with preclinical findings.
Specifically, LSD rapidly increased EGR1 and EGR2 expression in
the cortex in rats (Nichols and Sanders-Bush, 2002, 2004; Nichols
et al., 2003) and mice (Gonzalez-Maeso et al., 2003, 2007). We
expected similar rapid increases in EGR1 and EGR2 expression in
humans. Importantly, however, we evaluated gene expression in
human blood samples, whereas the animal studies evaluated gene
expression in brain tissue. Thus, it is possible that LSD alters gene
expression in the brain and not in blood.
Tolerance to repeated LSD administration reportedly begins
with the second daily dose of LSD, and complete tolerance
develops within 3–4 days of repeated LSD administration in
humans according to older studies (Cholden et al., 1955;
Abramson et al., 1956; Belleville et al., 1956; Passie et al., 2008;
Nichols, 2016) that need to be replicated. In the present study,
we found no evidence of acute pharmacological tolerance within
12 h of acute LSD administration at a dose of 100 µg as
documented in detail elsewhere (Dolder et al., 2017). Similarly,
no acute tolerance was observed after single-dose administration
of 200 µg LSD in humans within 24 h (Dolder et al., 2015b,
2017). Thus, after one dose of LSD, subjective effects of LSD
were self-reported by the participants as long as LSD was
present in plasma, and the subjective effects did not decline
more rapidly than the plasma concentrations of LSD (Dolder
et al., 2017). This is consistent with the view that LSD directly
activates 5-HT2A receptors to produce its mind-altering effects
as long as it is present in the effect compartment (i.e., the brain)
and assuming largely similar plasma and effect compartment
kinetics. The finding of no acute tolerance in the participants
in the present study (Dolder et al., 2017) also indicates that no
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FIGURE 1 | Lysergic acid diethylamide did not alter gene expression. The levels of expression of the 5-HT2A receptor gene (HTR2A) and early growth response
genes (EGR1, EGR2, and EGR3) were determined before and 1.5 and 24 h after administration of 100 µg LSD or placebo. The data are expressed as the
mean ± SEM of mRNA expression levels relative to reference genes with stable expression. The respective differences in fold-changes from baseline are show in
Table 2.
relevant counterregulatory neuroadaptations occurred or were
evident with the first 12–24 h after LSD administration. A recent
study showed that LSD dissociates very slowly from the 5-
HT2A receptor, and the authors proposed that the high potency
and long effect duration of LSD could be linked to a unique
receptor interaction (Wacker et al., 2017). However, the LSD
concentration-effect relationship (Dolder et al., 2017) shows that
the presence of LSD in the body sufficiently accounted for the
duration of its subjective effects. Doubling the LSD dose resulted
in prolongation of the effect by approximately 3 h, consistent
with its half-life of approximately 3 h (Dolder et al., 2017). In
contrast to the pharmacokinetic–pharmacodynamic relationship
of LSD (Dolder et al., 2017), other psychoactive substances,
such as 3,4-methylenedioxymethamphetamine (MDMA), exhibit
very marked acute pharmacological tolerance, with a rapid
decline of subjective and physiological effects of MDMA within
4 h despite continuously high plasma levels and a relatively
long half-life of 8 h (Hysek et al., 2010; Vizeli and Liechti,
2017).
LIMITATIONS
The present study has several limitations. First, we assessed the
effects of only an acute single dose of LSD on gene expression
and tolerance. Further repeated dose administration studies need
to be conducted. Second, we used only a moderate single dose of
LSD, and the study sample was relatively small. Third, we assessed
gene expression only at 1.5 and 24 h after LSD administration.
Therefore, we may have missed effects that may have occurred
between these time points. In fact, increases in EGR2 were
observed only up to 5 h in rats (Nichols and Sanders-Bush, 2002;
Gonzalez-Maeso et al., 2003; Nichols et al., 2003). Fourth, all
changes in gene expression that are caused by LSD that have
been reported to date have been observed animal brains, whereas
our study focused solely on human blood cells as a peripheral
biomarker of the central nervous system (Sullivan et al., 2006;
Mohr and Liew, 2007; Desjardins et al., 2008; Belzeaux et al., 2010;
Rollins et al., 2010; Rivera-Baltanas et al., 2014; Cattane et al.,
2015).
CONCLUSION
In summary, an acute single dose of LSD in humans did not
acutely alter the expression of the HTR2A and EGR1-3 genes in
peripheral mononuclear blood cells and thus did not influence
potential markers of neuroadaptation.
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